Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry
Overview
- Phase
- Not Applicable
- Intervention
- Statin
- Conditions
- Acute Coronary Syndrome
- Sponsor
- University Clinical Centre of Republic of Srpska
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Major Cardiovascular Adverse Events
- Last Updated
- 4 years ago
Overview
Brief Summary
Recent trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular adverse events following acute coronary syndrome (ACS). However, the data coming from the real-world setting are limited. Therefore, the aim of the study is to assess the association between LDL-C changes with prognosis in patients who survive ACS.
Patients with ACS will be followed for mortality and major events for at least 1 year. Changes in LDL-C between the ACS and a 6- to 10-week follow-up visit will be analysed. The associations between quartiles of LDL-C change and therapy intensity with outcomes will be investigated using adjusted Cox regression analyses.
Investigators
Bojan Stanetic
Assistant Prof. Bojan Stanetic, MD, PhD
University Clinical Centre of Republic of Srpska
Eligibility Criteria
Inclusion Criteria
- •acute coronary syndrome
Exclusion Criteria
- Not provided
Arms & Interventions
High-intensity statin
Intervention: Statin
High-intensity statin plus ezetimib
Intervention: Statin
High-intensity statin plus ezetimib plus PCSK9 inhibitor
Intervention: Statin
Outcomes
Primary Outcomes
Major Cardiovascular Adverse Events
Time Frame: 1 year
All-cause death, Acute Coronary Syndrom, Need for Myocardial Revascularization
Secondary Outcomes
- LDL reduction(1 year)